Bi-Specific Maker Covagen’s Series B To Progress Lead Asset COVA322
This article was originally published in The Pink Sheet Daily
Swiss biotech Covagen’s potential for engineering antibodies with two distinct binding specificities for a wide range of clinical applications as targeted agents has secured it a $47 million tranched Series B financing – which could rise to $63 million – to fund development of its lead asset, a bispecific TNF/IL-17A inhibitor.
You may also be interested in...
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.